Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma

Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor

(2016) Masahito Ogasawara et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Therapeutic implication of genetic variants ofIL13andSTAT4in airway remodelling with bronchial asthma

(2016) Y. Nakamura et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

(2016) Nicola A Hanania et al.   Lancet Respiratory Medicine

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

(2015) Nicola A Hanania et al.   THORAX

Periostin in the bronchial lavage fluid of asthma patients

(2015) Yutaka Nakamura et al.   ALLERGOLOGY INTERNATIONAL

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial

(2015) Christopher E Brightling et al.   Lancet Respiratory Medicine

Targeting Interleukin-13 with Tralokinumab Attenuates Lung Fibrosis and Epithelial Damage in a Humanized SCID Idiopathic Pulmonary Fibrosis Model

(2014) Lynne A. Murray et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study

(2014) Silvio Danese et al.   GUT

g_mmpbsa—A GROMACS Tool for High-Throughput MM-PBSA Calculations

(2014) Rashmi Kumari et al.   Journal of Chemical Information and Modeling

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids

(2013) Michael Noonan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids

(2013) Yoshihiro Kanemitsu et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab

(2013) Mark Ultsch et al.   JOURNAL OF MOLECULAR BIOLOGY

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

(2012) Edward Piper et al.   EUROPEAN RESPIRATORY JOURNAL

Lebrikizumab Treatment in Adults with Asthma

(2011) Jonathan Corren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Genetic Variation of IL-13 on Airway Remodeling in Bronchial Asthma

(2011) Hiromi Nagashima et al.   ALLERGOLOGY INTERNATIONAL